Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 10/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.64 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6187620 | 0.92 | CHRNB2 (0.63) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL650890 | 0.85 | CHRNB2 (0.70) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL650891 | 0.85 | CHRNB2 (0.70) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL652205 | 0.84 | CHRNB2 (0.68) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL652204 | 0.84 | CHRNB2 (0.68) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL5379807 | 0.83 | CHRNB4 (0.68) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL5375748 | 0.83 | CHRNB4 (0.68) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL5373931 | 0.83 | CHRNB2 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6190513 | 0.83 | CHRNB2 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6189093 | 0.83 | CHRNA4 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274710-B1 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NEUROSEARCH AS (DK) | 2005-02-23 | — | — | EP | claimed |
| US-6815438-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | NEUROSEARCH A/S (DK) | 2004-11-09 | — | — | US | claimed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | claimed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | claimed |
| EP-1274710-A2 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NeuroSearch A/S (DK) | 2003-01-15 | — | — | EP | claimed |
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | NEUROSEARCH A/S (DK) | 2003-01-02 | — | — | US | claimed |
| WO-2001044243-A2 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NEUROSEARCH A/S (DK) | 2001-06-21 | — | — | WO | claimed |
| EP-1359152-B1 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LAB (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7265115-B2 | Diazabicyclic CNS active agents | ABBOTT LABORATORIES (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1274710-B1 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NEUROSEARCH AS (DK) | 2005-02-23 | — | — | EP | disclosed |
| US-6815438-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | NEUROSEARCH A/S (DK) | 2004-11-09 | — | — | US | disclosed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1147112-B1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LAB (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | NEUROSEARCH A/S (DK) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | CHRNA2, CHRNA5, CHRNA6 | CHRNB4 11/4885CHRNA3 5/4885CHRNB2 6/4885 |
| US-20030225268-A1 | Diazabicyclic CNS active agents | GABRE, GRIN1, CNTN1 | CHRNB4 37/4885CHRNA3 23/4885CHRNB2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.